Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%–30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively in...

Full description

Bibliographic Details
Main Authors: Felicia Stefania Falvella, Marta Caporale, Stefania Cheli, Antonia Martinetti, Rosa Berenato, Claudia Maggi, Monica Niger, Francesca Ricchini, Ilaria Bossi, Maria Di Bartolomeo, Elisa Sottotetti, Francesca Futura Bernardi, Filippo de Braud, Emilio Clementi, Filippo Pietrantonio
Format: Article
Language:English
Published: MDPI AG 2015-04-01
Series:International Journal of Molecular Sciences
Subjects:
single nucleotide polymorphisms
fluoropyrimidines
dihydropyrimidine dehydrogenase
toxicity
pharmacogenetics
Online Access:http://www.mdpi.com/1422-0067/16/4/8884

Internet

http://www.mdpi.com/1422-0067/16/4/8884

Similar Items